

Outpatient Antibiogram 2021- Urine Source only

Gram Negative-Urine Only

Organisms	Aminoglycosides			Beta lactam/beta lactam inhibitors			Carbapenems			Cephalosporin Class			Fluoroquinolones		Folate pathway inhibitor	Fosfomycin	Monobactams	Nitrofurans			
	Amikacin	Gentamicin	Tobramycin	Aminocillin/Clavulanic acid	Ampicillin	Ampicillin/Sulbactam	Piperacillin/Tazobactam	Ertapenem	Imipenem	Meropenem	Cefazolin	Cefazolin Urine	Cefepime	Ceftazidime	Ceftioxone	Ciprofloxacin	Levofloxacin	Trimethoprim/Sulfamethoxazole	Fosfomycin	Aztreonam	Nitrofurantoin
Citrobacter freundii complex (2)	100	50	0	0	0	0	100	100	100	100	0				50	50	50	50			50
Enterobacter cloacae complex (9)	100	100	0	0	0	0	100	100		100	0				100	100	88	88	88		11
Escherichia coli (137)	89	89	87	66	70	97	100	100	100		83				99	98	82	83	83		99
Escherichia coli, ESBL (14)	64	64					100	100	92							14	71	42	92		64
Klebsiella pneumoniae (14)	97	97	91	0	85	97	100	100	100		78				100	97	97	100	91		39
Klebsiella pneumoniae, ESBL (2)	50	50					100	100	100							50	50	50			0
Proteus mirabilis (11)	90	90	100	90	100	100	100				0				100	100	100	100	90		0
Pseudomonas aeruginosa (14)	100	100	100				100	92				100	100		100	100				85	
Citrobacter koseri (10)	100	100	100	0	100	100	100	100	100	100					100	100	100	100			60
Klebsiella aerogenes (3)	100	100	0	0	0	66	100			100	0				66	66	100	100	100		33
Klebsiella oxytoca/Kaoitella ornithinolytica (7)	100	100	100	0	28	100	100	100	100	0					100	100	100	100			71
Klebsiella varicola (2)	100	100	100	0	100	100	100	100	100	100					100	100	100	100			100

Cefazolin predicts results for the oral agents-Cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime axetil and loracarbef when used for therapy of uncomplicated UTI's due to E. coli, K. pneumoniae, and P. mirabilis. A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only.

COMMENTS:

- Data are obtained from MIC and disk diffusion testing methods.
- Isolate counts are in parenthesis to the right of the organism name.
- MRSA (methicillin resistant Staph aureus): In 2021, 168 of 553 (30.3%) Staph aureus were MRSA. Prior years were as follows: 2020-30.0%, 2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 - 52.5%.
- ESBL (extended spectrum beta lactamases): In 2021, 226 of 2,889 (7.8%) E. coli isolates (combined inpatient and outpatient) produced ESBL. Prior years were as follows: 2020-7.3%, 2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.
- Penicillin Resistant Streptococcus pneumoniae: In 2021, no Penicillin Resistant Streptococcus pneumoniae. Prior year were as follows: 2020, no Penicillin Resistant Streptococcus pneumoniae, 2019, 1 of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillin resistant.

Outpatient Antibigram 2021- Urine Source only

Gram positive-Urine only		Aminoglycosides	Ansamycin	Beta lactam/Beta lactam inhibitors		Cephalosprin Class	Fluoroquinolones	Folate pathway inhibitor	Glycopeptides	Lipopeptides	Nitrofurans	oxazolidinones
	Organisms	Tetracycline	Gentamicin	Rifampin	Ampicillin	Oxacillin	Cefazolin	Levofloxacin	Trimethoprim/Sulfamethoxazole	Vancomycin	Deptomycin	Nitrofurantoin
Enterococcus faecalis (34)	35			100			94		100		100	100
Staphylococcus epidermidis (3)	100	100	100		33	33	66		100	100	100	100
Staphylococcus aureus (3)	100	100	100		100	100	66	100	100	100	100	100

A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only.

COMMENTS:

1. Data are obtained from MIC and disk diffusion testing methods.
2. Isolate counts are in parenthesis to the right of the organism name.
3. MRSA (methicillin resistant Staph aureus): In 2021, 168 of 553 (30.3%) Staph aureus were MRSA. Prior years were as follows: 2020-30.0 %, 2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 - 52.5%.
4. ESBL (extended spectrum beta lactamases): In 2021, 226 of 2,889 (7.8%) Ecoli isolates (combined inpatient and outpatient) produced ESBL . Prior years were as follows: 2020-7.3%, 2019- 8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.
5. Penicillin Resistant Streptococcus pneumoniae: In 2021, no Penicillin Resistant Streptococcus pneumoniae. Prior year were as follows: 2020, no Penicillin Resistant Streptococcus pneumoniae, 2019, 1 of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillin resistant.

Outpatient Antibiogram 2021-Non Urine Source only

Gram positive- Non Urine Only

Organisms	Aminoglycosides			Ansamycin	Beta lactam/Beta lactam inhibitors		Cephalosporin Class		Fluoroquinolones	Folate pathway inhibitor	Glycopeptides	Lincosamides	Lipopeptides	Macrolides	oxazolidinones
	Tetracycline	Gentamicin	Gentamicin Synergy Screen		Rifampin	Ampicillin	Oxacillin	Cefazolin							
Enterococcus faecalis (19)			84		100						100		100		100
Enterococcus faecium (1)			100		100						100		100		100
Staphylococcus epidermidis (3)	0	100		100		33	33		33		100	100	100	0	100
Staphylococcus aureus (53)	92	98		100		100	100		77	98	100	75	100	60	100
Methicillin Resistant Staphylococcus aureus (17)	82	82		94		0	0	100	23	100	100	52	100	29	100

A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only.

COMMENTS:

1. Data are obtained from MIC and disk diffusion testing methods.
2. Isolate counts are in parenthesis to the right of the organism name.
3. MRSA (methicillin resistant Staph aureus): In 2021, 168 of 553 (30.3%) Staph aureus were MRSA. Prior years were as follows: 2020-30.0%, 2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 -52.5%.
4. ESBL (extended spectrum beta lactamases): In 2021, 226 of 2,889 (7.8%) Ecoli isolates (combined inpatient and outpatient) produced ESBL. Prior years were as follows: 2020-7.3%, 2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.
5. Penicillin Resistant Streptococcus pneumoniae: In 2021, no Penicillin Resistant Streptococcus pneumoniae. Prior year were as follows: 2020, no Penicillin Resistant Streptococcus pneumoniae, 2019, 1 of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillin resistant.

Outpatient Antibigram 2021- Non Urine Source only

Gram Negative -Non-Urine Only	Aminoglycosides			Beta lactam/Beta lactam inhibitors			Carbapenems			Cephalosporin Cla				Fluoroquinolones		Folate pathway inhibitor	Monobactams	
	Amikacin	Genamycin	Tobramycin	Amoxicillin/Clavulanate	Ampicillin	Ampicillin/Sulbactam	Piperacillin/Tazobactam	Ertapenem	Imipenem	Meropenem	Cefazolin	Cefepime	Ceftazidime	Ceftioxone	Ciprofloxacin	Levofloxacin	Trimethoprim/Sulfamethoxazole	Acetronam
Citrobacter freundii complex (1)	100	100	0	0	0	100	100	100	100	0	0	100	100	100	100	100	100	100
Enterobacter cloacae complex (8)	100	100	0	0	0	100	100	100	100	0	0	100	100	100	100	100	75	
Escherichia coli (23)	86	82	73	30	34	100	100	100	100	56	0	95	95	78	78	65		
Klebsiella pneumoniae (5)	100	100	100	0	100	100	100	100	100	100	0	100	100	80	80	100		
Proteus mirabilis (17)	94	88	94	88	100	100	93			0	0	100	100	70	70	76		
Pseudomonas aeruginosa (27)	100	96	100				92		100	96		92	96	81	77			88

A valid statistical analysis should include 30 or more isolates, organisms with less than 30 isolates are listed for informational purpose only.

COMMENTS:

- Data are obtained from MIC and disk diffusion testing methods.
- Isolate counts are in parenthesis to the right of the organism name.
- MRSA (methicillin resistant Staph aureus): In 2021, 168 of 553 (30.3%) Staph aureus were MRSA. Prior years were as follows: 2020-30.0 %, 2019-36.7%, 2018 - 39.4%, 2017 - 37.8%, 2016 - 41.3%, 2015 - 35.6%, 2014 - 52.5%.
- ESBL (extended spectrum beta lactamases): In 2021, 226 of 2,889 (7.8%) Ecoli isolates (combined inpatient and outpatient) produced ESBL. Prior years were as follows: 2020-7.3%, 2019-8.27%, 2018 - 8.3%, 2017 - 7.5%, 2016 - 8.1%, 2015 - 8.3%, 2014 - 6.8%, 2013 - 5%.
- Penicillin Resistant Streptococcus pneumoniae: In 2021, no Penicillin Resistant Streptococcus pneumoniae. Prior year were as follows: 2020, no Penicillin Resistant Streptococcus pneumoniae, 2019, 1 of 34 (2.94%) Streptococcus pneumoniae isolates (combined inpatient and outpatient) were Penicillin resistant.